Radiofrequency ablation of hepatocellular cancer in 110 patients with cirrhosis.

F Izzo
F Izzo
National Cancer Institute

Ann Surg 2000 Sep;232(3):381-91

Department of Surgical Oncology, The University of Texas M.D. Anderson Cancer Center, Houston, Texas 77030, USA.

Objective: To determine the treatment efficacy, safety, local tumor control, and complications related to radiofrequency ablation (RFA) in patients with cirrhosis and unresectable hepatocellular carcinoma (HCC).

Summary Background Data: Most patients with HCC are not candidates for resection because of tumor size, location, or hepatic dysfunction related to cirrhosis. RFA is a technique that permits in situ destruction of tumors by means of local tissue heating.

Methods: One hundred ten patients with cirrhosis and HCC (Child class A, 50; B, 31; C, 29) were treated during a prospective study using RFA. Patients were treated with RFA using an open laparotomy, laparoscopic, or percutaneous approach with ultrasound guidance to place the RF needle electrode into the hepatic tumors. All patients were followed up at regular intervals to detect treatment-related complications or recurrence of disease.

Results: All 110 patients were followed up for at least 12 months after RFA (median follow-up 19 months). Percutaneous or intraoperative RFA was performed in 76 (69%) and 34 patients (31%), respectively. A total of 149 discrete HCC tumor nodules were treated with RFA. The median diameter of tumors treated percutaneously (2.8 cm) was smaller than that of lesions treated during laparotomy (4.6 cm). Local tumor recurrence at the RFA site developed in four patients (3.6%); recurrent HCC subsequently developed in other areas of the liver in all four. New liver tumors or extrahepatic metastases developed in 50 patients (45. 5%), but 56 patients (50.9%) had no evidence of recurrence. There were no treatment-related deaths, but complications developed in 14 patients (12.7%) after RFA.

Conclusions: In patients with cirrhosis and HCC, RFA produces effective local control of disease in a significant proportion of patients and can be performed safely with minimal complications.

Download full-text PDF


Still can't find the full text of the article?

Sign up to send a request to the authors directly.
September 2000
16 Reads

Publication Analysis

Top Keywords

patients cirrhosis
developed patients
110 patients
local tumor
treated rfa
radiofrequency ablation
cirrhosis hcc
rfa patients
rfa median
69% patients
months percutaneous
performed 69%
percutaneous intraoperative
patients 31%
intraoperative rfa

Similar Publications

HSV-Induced Systemic Inflammation as an Animal Model for Behçet's Disease and Therapeutic Applications.

Viruses 2018 09 19;10(9). Epub 2018 Sep 19.

Department of Biomedical Science, Ajou University School of Medicine, Suwon 16499, Korea.

Behçet's disease (BD) affects multiple organs. It is mainly characterized by recurrent oral, skin, and genital aphthous ulcers, and eye involvement. Successful management of BD is increasing, although its etiology remains unclear. Read More

View Article
September 2018
26 Reads
3.28 Impact Factor

Two-Dimensional Versus Three-Dimensional Laparoscopic Systems in Urology: A Systematic Review and Meta-Analysis.

J Endourol 2018 Sep;32(9):781-790

Department of Urology, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology , Wuhan, P.R. China .

Background: Laparoscopy is widely used in the urological field. This systematic review and a meta-analysis were conducted to assess the clinical and surgical efficacy of the three-dimensional (3D) laparoscopic system in comparison with two-dimensional (2D) laparoscopy for treatment of different urological conditions.

Methods: Following guidelines of Preferred Reporting Items for Systematic Reviews and Meta-Analyses, a systematic literature search in Web of Science, PubMed, Cochrane Library, and EMBase was carried out to identify relevant studies published up to May 2018. Read More

View Article
September 2018
54 Reads
2.10 Impact Factor

CD4 cell count response to first-line combination ART in HIV-2+ patients compared with HIV-1+ patients: a multinational, multicohort European study.

J Antimicrob Chemother 2017 10;72(10):2869-2878

Assistance Publique-Hôpiteaux de Paris, Hôpital Bichat-Claude Bernard, Paris, France.

Background: CD4 cell recovery following first-line combination ART (cART) is poorer in HIV-2+ than in HIV-1+ patients. Only large comparisons may allow adjustments for demographic and pretreatment plasma viral load (pVL).

Methods: ART-naive HIV+ adults from two European multicohort collaborations, COHERE (HIV-1 alone) and ACHIeV2e (HIV-2 alone), were included, if they started first-line cART (without NNRTIs or fusion inhibitors) between 1997 and 2011. Read More

View Article
October 2017
39 Reads
1 PubMed Central Citation(source)
5.31 Impact Factor

A Web-based interactive diabetes registry for health care management and planning in Saudi Arabia.

J Med Internet Res 2013 Sep 9;15(9):e202. Epub 2013 Sep 9.

Strategic Center for Diabetes Research, University Diabetes Centre, King Saud University, Riyadh, Saudi Arabia.

Background: Worldwide, eHealth is a rapidly growing technology. It provides good quality health services at lower cost and increased availability. Diabetes has reached an epidemic stage in Saudi Arabia and has a medical and economic impact at a countrywide level. Read More

View Article
September 2013
14 Reads
13 PubMed Central Citations(source)
3.43 Impact Factor

Breast cancer clinicopathological presentation, gravity and challenges in Eritrea, East Africa: management practice in a resource-poor setting.

S Afr Med J 2013 Jun 5;103(8):526-8. Epub 2013 Jun 5.

Orotta School of Medicine and Dentistry, Asmara, Eritrea.

Background: In Africa, breast cancer closely compares with cervical cancer as the most common malignancy affecting women and the incidence rates appear to be rising. Early detection of breast cancer is a key strategy for a good treatment outcome. However, there is no established protocol or guideline for management of breast cancer in Eritrea, East Africa. Read More

View Article
June 2013
18 Reads
7 PubMed Central Citations(source)
1.71 Impact Factor